Navigation Links
Lamictal as add-on therapy for children with epilepsy

The U.S. Food and Drug Administration has approved GlaxoSmithKline's new drug Lamictal (lamotrigine) as an addition for children whose partial seizures are inadequately controlled on their existing therapy. This new indication is an expansion of the //already-approved indications for adjunctive use in adults with partial seizures, and for the generalized seizures of Lennox-Gastaut Syndrome in children two years of age and older.

Partial seizures are the most common type of epilepsy and they begin with abnormal electrical activity in a particular location in the brain. The effect of these seizures include lip smacking, a dazed state or jerking movements of certain body parts.

The approval of the drug was based on a clinical study that demonstrated the efficacy of the drug as add-on therapy in pediatric patients who were still having frequent partial seizures (at least four per month) despite optimal doses of other anti-epilepsy drugs (AEDs). The study was a 18 week placebo controlled study in which 200 patients aged between 2 and 15 years, who were still having frequent seizures despite use of other AEDs, were randomized to treatment with Lamictal or placebo added to their current AED regimen of up to two drugs (Lamictal: 99, placebo: 101). The results showed significant reductions in the frequency of all partial seizures in children and adolescents with epilepsy when Lamictal was added to their AED regimen.

Michael Duchowny, director of the Comprehensive Epilepsy Program at Miami Children's Hospital said that Lamictal would be a welcome addition as FDA-approved therapies for children with epilepsy are limited and any clinically proven medication which can effectively control seizures in children would be an important new option to manage this condition.


'"/>




Page: 1

Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. Analysis Shows Lamictal As An Effective Additional Therapy For Treatment of Grand Mal Seizures
3. FDA Decision Encourages Lamictal Generics
4. Acupuncture May Help Chemotherapy Side Effects
5. Antioxidants protect health tissue in people undergoing radiation therapy.
6. Distraction therapy found very effective in postoperative patients
7. Acupuncture superseeds massage therapy for short term relief of pain
8. Ovarian cancer in relationship with Hormone therapy
9. New therapy better at increasing bone density
10. Gene therapy - Aim to improve blood flow
11. Gene therapy restores sight
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: